|
[1]CHEN JG.Trends in the incidence of liver cancer and its primaryprevention in China[J].J Clin Hepatol, 2012, 28 (4) :256-260. (in Chinese) 陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志, 2012, 28 (4) :256-260.
|
|
[2]de LOPE CR, TREMOSINI S, FORNER A, et al.Management of HCC[J].J Hepatol, 2012, 56 (Suppl 1) :s75-s87.
|
|
[3]TAN DS, THOMAS GV, GARRETT MD, et al.Biomarker-drivenearly clinical trials in oncology:a paradigm shift in drug develop-ment[J].Cancer J, 2009, 15 (5) :406-420.
|
|
[4]GILLMORE R, STUART S, KIRKWOOD A, et al.EASL and mRECISTresponses are independent prognostic factors for survival in hepatocellularcancer patients treated with transarterial embolization[J].J Hepatol, 2011, 55 (6) :1309-1316.
|
|
[5]SHIM JH, LEE HC, KIM SO, et al.Which response criteria besthelp predict survival of patients with hepatocellular carcinoma fol-lowing chemoembolization?A validation study of old and new models[J].Radiology, 2012, 262 (2) :708-718.
|
|
[6]European Association for the Study of the Liver, European Organisa-tion for Research and Treatment of Cancer.EASL-EORTC clinicalpractice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.
|
|
[7]LEUNG TW, PATT YZ, LAU WY, et al.Complete pathologicalremission is possible with systemic combination chemotherapy for in-operable hepatocellular carcinoma[J].Clin Cancer Res, 1999, 5 (7) :1676-1681.
|
|
[8]NIE RH, LIU YY.Application of detection of tumor markers AFP, CA125, CA199 and CEA in diagnosis and treatment for patientswith hepatitis and liver cirrhosis[J].J Jilin Univ:Med Edit, 2012, 38 (1) :119-122. (in Chinese) 聂荣慧, 刘元元.肿瘤标志物AFP、CA125、CA199和CEA检测在肝炎、肝硬化患者诊断和治疗中的应用[J].吉林大学学报:医学报, 2012, 38 (1) :119-122.
|
|
[9]AOYAGI Y, SUZUKI Y, IGARASHI K, et al.Carbohydrate struc-tures of human alpha-fetoprotein of patients with hepatocellularcarcinoma:presence of fucosylated and non-fucosylated trianten-nary glycans[J].Br J Cancer, 1993, 67 (3) :486-492.
|
|
[10]NOMURA F, OHNISHI K, TANABE Y.Clinical features andprognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels.Analysis of 606 patients[J].Cancer, 1989, 64 (8) :1700-1707.
|
|
[11]IZUMI R, SHIMIZU K, KIRIYAMA M, et al.Alpha-fetoprotein pro-duction by hepatocellular carcinoma is prognostic of poor patient surviv-al[J].J Surg Oncol, 1992, 49 (3) :151-155.
|
|
[12]PENG SY, CHEN WJ, LAI PL, et al.High alpha-fetoprotein lev-el correlates with high stage, early recurrence and poor prognosis ofhepatocellular carcinoma:significance of hepatitis virus infection, age, p53 and beta-catenin mutations[J].Int J Cancer, 2004, 112 (1) :44-50.
|
|
[13]KOHLES N, NAGEL D, JUNGST D, et al.Prognostic relevance ofoncological serum biomarkers in liver cancer patients undergoingtransarterial chemoembolization therapy[J].Tumour Biol, 2012, 33 (1) :33-40.
|
|
[14]GIANNINI EG, MARENCO S, BORGONOVO G, et al.Alpha-fetoprotein has no prognostic role in small hepatocellular carcinomaidentified during surveillance in compensated cirrhosis[J].Hepa-tology, 2012, 56 (4) :1371-1379.
|
|
[15]XU XS, QU K, LIU C, et al.Highlights forα-fetoprotein in de-termining prognosis and treatment monitoring for hepatocellular car-cinoma[J].World J Gastroenterol, 2012, 18 (48) :7242-7250.
|
|
[16]TSAI MC, WANG JH, HUNG CH, et al.Favorable alpha-feto-protein decrease as a prognostic surrogate in patients with hepatocel-lular carcinoma after radiofrequency ablation[J].J GastroenterolHepatol, 2010, 25 (3) :605-612.
|
|
[17]KAO WY, CHIOU YY, HUNG HH, et al.Serum alpha-fetopro-tein response can predict prognosis in hepatocellular carcinoma pa-tients undergoing radiofrequency ablation therapy[J].Clin Radiol, 2012, 67 (5) :429-436.
|
|
[18]RIAZ A, RYU RK, KULIK LM, et al.Alpha-fetoprotein response afterlocoregional therapy for hepatocellular carcinoma:oncologic marker of ra-diologic response, progression, and survival[J].J Clin Oncol, 2009, 27 (34) :5734-5742.
|
|
[19]MEMON K, KULIK L, LEWANDOWSKI RJ, et al.Alpha-feto-protein response correlates with EASL response and survival in soli-tary hepatocellular carcinoma treated with transarterial therapies:asubgroup analysis[J].J Hepatol, 2012, 56 (5) :1112-1120.
|
|
[20]PARK WH, SHIM JH, HAN SB, et al.Clinical utility of des-gamma-carboxyprothrombin kinetics as a complement to radiologicresponse in patients with hepatocellular carcinoma undergoingtransarterial chemoembolization[J].J Vasc Interv Radiol, 2012, 23 (7) :927-936.
|
|
[21]LEE YK, KIM SU, KIM do Y, et al.Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in pa-tients with hepatocellular carcinoma treated with transarterial chemo-embolization[J].BMC Cancer, 2013, 13 (1) :5.
|
|
[22]SHAO YY, LIN ZZ, HSU C, et al.Early alpha-fetoprotein re-sponse predicts treatment efficacy of antiangiogenic systemic therapyin patients with advanced hepatocellular carcinoma[J].Cancer, 2010, 116 (19) :4590-4596.
|
|
[23]YAU T, YAO TJ, CHAN P, et al.The significance of early alpha-fe-toprotein level changes in predicting clinical and survival benefits in ad-vanced hepatocellular carcinoma patients receiving sorafenib[J].On-cologist, 2011, 16 (9) :1270-1279.
|
|
[24]PERSONENI N, BOZZARELLI S, PRESSIANI T, et al.Useful-ness of alpha-fetoprotein response in patients treated with sorafenibfor advanced hepatocellular carcinoma[J].J Hepatol, 2012, 57 (1) :101-107.
|
|
[25]KIM BK, AHN SH, SEONG JS, et al.Early alpha-fetoprotein re-sponse as a predictor for clinical outcome after localized concurrentchemoradiotherapy for advanced hepatocellular carcinoma[J].LiverInt, 2011, 31 (3) :369-376.
|
|
[26]LEE MH, KIM SU, KIM do Y, et al.Early on-treatment predic-tions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepato-cellular carcinoma[J].J Gastroenterol Hepatol, 2012, 27 (2) :313-322.
|
|
[27]CHEN LT, LIU TW, CHAO Y, et al.alpha-fetoprotein response pre-dicts survival benefits of thalidomide in advanced hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2005, 22 (3) :217-226.
|
|
[28]KEAM B, OH DY, LEE SH, et al.A Phase II study of 5-fluorou-racil and cisplatin systemic chemotherapy for inoperable hepatocellu-lar carcinoma with alpha fetoprotein as a predictive and prognosticmarker[J].Mol Med Report, 2008, 1 (3) :415-422.
|
|
[29]CHAN SL, MO FK, JOHNSON PJ, et al.New utility of an oldmarker:serial alpha-fetoprotein measurement in predicting radio-logic response and survival of patients with hepatocellular carcinomaundergoing systemic chemotherapy[J].J Clin Oncol, 2009, 27 (3) :446-452.
|
|
[30]VORA SR, ZHENG H, STADLER ZK, et al.Serum alpha-feto-protein response as a surrogate for clinical outcome in patients re-ceiving systemic therapy for advanced hepatocellular carcinoma[J].Oncologist, 2009, 14 (7) :717-725.
|
|
[31]BAI W, HAN GH.Comprehensive intervention treatment for hepa-tocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :36-37, 41. (in Chinese) 白苇, 韩国宏.肝细胞癌的综合介入治疗[J].临床肝胆病杂志, 2013, 29 (1) :36-37, 41.
|
DownLoad: